[The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]
- PMID: 219640
[The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]
Abstract
The MVA virus is a lab virus ideally suited for vaccination of both man and animal which can be differentiated from the known Vaccinia strains by the use of numerous biological markers. Its reduced virulence for the chick embryo, for experimental animals and for man is a particularly characteristic feature. With the exception of chick embryo fibroblasts, the MVA virus grows in cell cultures only abortively. This applies particularly to cells of human origin in which the cytopathic effect and plaque formation are completely missing. The restriction analysis of the DNS of the MVA virus demonstrates that its genetic structure differs from that of the CVA basic virus and other orthopox viruses. In contrast to the WHO reference strain Elstree, the MVA virus has a genome shortened by about 9 per cent. The use of the MVA virus for human vaccination is particularly indicated in persons to be vaccinated for the first time and likely to entail a risk (on account of allergies etc.) because it brings about a state of revaccination without complications. The MVA virus can be administered in intracutaneous, subcutaneous or intramuscular injections. Innocuoursness and successful vaccination have been demonstrated in more than 120000 persons. While other Vaccinia strains, such as the Elstree virus, experience a drastic increase of virulence in the immunosuppressed organism (subjected to whole-body irradiation), the MVA virus cannot be activated not even in this situation.
Similar articles
-
[Development of a numerically additive combined vaccine against tetanus and smallpox].Zentralbl Bakteriol Mikrobiol Hyg A. 1985 Apr;259(2):206-18. Zentralbl Bakteriol Mikrobiol Hyg A. 1985. PMID: 2990123 German.
-
[An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola (author's transl)].Zentralbl Bakteriol Orig A. 1975;230(3):283-97. Zentralbl Bakteriol Orig A. 1975. PMID: 1146441 German.
-
Vaccination against pox diseases under immunosuppressive conditions.Dev Biol Stand. 1978;41:225-34. Dev Biol Stand. 1978. PMID: 223909
-
Smallpox vaccination and bioterrorism with pox viruses.Comp Immunol Microbiol Infect Dis. 2003 Oct;26(5-6):423-30. doi: 10.1016/S0147-9571(03)00025-0. Comp Immunol Microbiol Infect Dis. 2003. PMID: 12818626 Review.
-
[Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA].Berl Munch Tierarztl Wochenschr. 1994 Aug;107(8):253-6. Berl Munch Tierarztl Wochenschr. 1994. PMID: 7945180 Review. German.
Cited by
-
Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer.Clin Med Insights Oncol. 2012;6:67-73. doi: 10.4137/CMO.S7654. Epub 2012 Jan 5. Clin Med Insights Oncol. 2012. PMID: 22253556 Free PMC article.
-
Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates.Front Immunol. 2023 Dec 12;14:1264323. doi: 10.3389/fimmu.2023.1264323. eCollection 2023. Front Immunol. 2023. PMID: 38155964 Free PMC article.
-
Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.J Virol. 2002 Aug;76(15):7713-23. doi: 10.1128/jvi.76.15.7713-7723.2002. J Virol. 2002. PMID: 12097585 Free PMC article.
-
Different levels of immunogenicity of two strains of Fowlpox virus as recombinant vaccine vectors eliciting T-cell responses in heterologous prime-boost vaccination strategies.Clin Vaccine Immunol. 2006 Jul;13(7):747-57. doi: 10.1128/CVI.00088-06. Clin Vaccine Immunol. 2006. PMID: 16829611 Free PMC article.
-
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.Vaccine. 2007 Dec 12;25(51):8562-73. doi: 10.1016/j.vaccine.2007.10.017. Epub 2007 Oct 26. Vaccine. 2007. PMID: 18036708 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous